Press release
Zhonghan Biotech's Abemaciclib Intermediates: High-Quality Key Intermediates Empowering Efficient Synthesis of CDK4/6 Inhibitors
Jinan Zhonghan Chemical Technology Co., Ltd. focuses on the R&D and large-scale production of high-end pharmaceutical intermediates. Relying on mature processes, strict quality control and customized production capacity, we have launched a series of high-purity key intermediates for Abemaciclib, covering key nodes of core skeleton construction and side chain synthesis, providing pharmaceutical enterprises with stable, compliant and cost-effective raw material support
Product Positioning and Core Value
Our Abemaciclib Intermediates [https://www.xsu.com/abemaciclib-intermediates-1/] are positioned to meet the needs of commercial API production, with the core advantages of high purity, low impurities, stable process and scalability. They are suitable for the whole process from laboratory small-scale test to industrial mass production, helping customers shorten R&D cycles, reduce production costs, and improve pharmaceutical compliance and market competitiveness.
Image: https://www.abnewswire.com/upload/2026/03/535cbfda0eda36c1a0c907ad5691f72b.jpg
Core Intermediates and Key Indicators
- 4-Bromo-2,6-difluoroaniline
CAS: 67567-26-4
Purity greater than or equal to 99.5%, single impurity less than or equal to 0.1%. Moisture and metal residues are strictly controlled. It is suitable for cyclization and coupling reactions with stable yield.
- N-Isopropylacetamide
CAS: 1118-69-0
As a key building block for amidination and cyclization, it features high purity and controllable impurities, supports continuous processes and improves the overall yield.
- Other Customized Intermediates: We provide one-stop services including custom development, process optimization and pilot scale-up according to customers' synthetic routes, meeting the needs of patent circumvention and differentiated synthesis.
Image: https://www.abnewswire.com/upload/2026/03/7bbbed271543443fa06ac12d684db105.jpg
Technical and Quality Advantages
* Mature and Stable Process: Adopting optimized synthetic routes with mild reaction conditions, few by-products and compliant three-waste treatment, suitable for continuous production.
* Stringent Quality System: Implementing the ISO9001 quality management system, establishing a full-item detection and traceability system for genotoxic impurities, heavy metals, residual solvents, etc., with strong batch consistency.
* Reliable Delivery Guarantee: Combining standardized production with flexible capacity, providing stable supply from gram-level to ton-level, supporting rapid response and long-term price locking.
* Professional Technical Support: Equipped with a professional R&D and technical service team, providing supporting services such as process parameters, post-treatment and purification schemes.
Application Scenarios
Our products are targeted at domestic and foreign API manufacturers, CDMO/CMO and innovative drug R&D institutions, used for the synthesis, process verification, registration application and commercial production of Abemaciclib API, fully meeting the compliance requirements of China NMPA, US FDA, EU CEP and other regulatory authorities.
About Zhonghan Biotech
Jinan Zhonghan Chemical Technology Co., Ltd. specializes in the R&D and preparation of high-value-added new drug intermediates and active small molecule inhibitors, focusing on therapeutic fields such as anti-tumor and cardiovascular diseases, integrating R&D, pilot test, production and sales. With modern production workshops, a professional R&D platform and a number of invention patents, the company adheres to the philosophy of innovation-driven, quality-oriented and customer-first, and continuously provides reliable raw materials and technical solutions for the global pharmaceutical industry.
Business and Technical Enquiry
For product COA, spectra, quotation and custom development solutions, please contact us:
Tel: [18562151612]
Email: [2289008634@qq.com]
Official Website: https://www.xsu.com/
Media Contact
Company Name: Jinan Zhonghan Chemical Technology Co., LTD.
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=zhonghan-biotechs-abemaciclib-intermediates-highquality-key-intermediates-empowering-efficient-synthesis-of-cdk46-inhibitors]
Country: China
Website: http://www.xsu.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Zhonghan Biotech's Abemaciclib Intermediates: High-Quality Key Intermediates Empowering Efficient Synthesis of CDK4/6 Inhibitors here
News-ID: 4430355 • Views: …
More Releases from ABNewswire
Sacramento, CA Printing Cost Breakdown: What Is Really Being Paid For: Materials …
Royal Prints breaks down what Sacramento businesses pay for in print orders, from materials and sign printing to labor, turnaround, and delivery, with no hidden fees.
SACRAMENTO, CA - August 16, 2026 - Print quotes across Sacramento continue to puzzle local business owners. A business card order from one printing company Sacramento locals rely on might come back at $85 for 500 pieces, while another vendor quotes $220 for the exact…
Independent Etsy Brand Naughty Chicken Tees Proves Small Business Creativity Can …
Naughty Chicken Tees exemplifies the growing power of independent creators in the American fashion market, offering chicken-themed graphic tees that rival larger brands in design quality and customer appeal. The Etsy storefront has become a destination for shoppers seeking original apparel that cannot be found on conventional retail shelves.
The American fashion industry has traditionally been dominated by large corporations with massive marketing budgets and extensive retail networks. But the rise…
Bob Kevess, MD, Examines How Patient-Centered Primary Care Supports Better Healt …
Healthcare leader discusses how communication, continuity, and preventive care strengthen the relationship between physicians and adult patients
BERKELEY, Calif. - Aug 15, 2026 - As healthcare systems continue shifting toward value-based care and prevention-focused models, physicians and healthcare organizations are placing renewed emphasis on patient-centered primary care. Rather than focusing solely on diagnosing and treating disease, this approach encourages long-term partnerships between patients and healthcare providers, recognizing that informed, engaged individuals…
Local Practice Offering Teen Therapy in Claremont, CA Addresses Growing Mental H …
Image: http://www.abnewswire.com/pressreleases/wp-content/uploads/2026/08/2026
Claremont, CA - August 14, 2026 - Today's teenagers face a complex landscape of academic pressure, social media exposure, identity challenges, and family transitions that can take a serious toll on mental health. Aspire Therapy Center - Claremont, CA Counselor office, founded in 2012 with its Claremont location opening in 2018, has become a trusted resource for adolescents and their families navigating these demands. Under the leadership of Melissa…
More Releases for Abemaciclib
Worldwide Trends Overview: The Rapid Development of the Abemaciclib Market
The market for abemaciclib, a targeted cancer therapy, is anticipated to experience substantial growth over the next several years. Fueled by advances in precision oncology and expanding treatment options, this market is expected to reach significant valuations by 2030. Let's explore the market size projections, key players driving innovation, emerging trends, and the segmentation details shaping the abemaciclib landscape.
Projected Market Value and Growth Trajectory of the Abemaciclib Market
By…
Segmentation, Leading Trends, and Competitive Overview of the Abemaciclib Market
The abemaciclib market is poised for substantial expansion over the coming years, driven by advances in cancer treatment and increasing demand for precision medicine. This sector is gaining momentum due to innovations in targeted therapies and evolving treatment protocols, especially for breast cancer patients. Below is an insightful overview of the market's size, key players, emerging trends, and segmentation.
Projected Growth and Market Size of the Abemaciclib Industry
The abemaciclib…
Abemaciclib Market Share Analysis Across Monotherapy Combination Therapy and Adv …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Abemaciclib Market Size, Share & Trends Analysis Report, By Therapy Type (Monotherapy (Abemaciclib Alone) and Combination Therapy (with Endocrine Therapy, other Cancer Drugs)), By Indication (Early Breast Cancer (HR-positive, HER2-negative), Advanced or Metastatic Breast Cancer (HR-positive, HER2-negative), and Other Cancer Types), By Dosage Strength (50 mg, 100 mg, 150 mg, and 200 mg), By Line…
Abemaciclib Market Set to Significantly Grow from 2025 to 2032 |Eli Lilly and Co …
The Global Abemaciclib Market is estimated to be valued at USD 1.94 Bn in 2025 and is expected to reach USD 4.48 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2025 to 2032.
The latest report from Coherent Market Insights examines the growth prospects of the Abemaciclib Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth factors,…
Abemaciclib Market Poised to Hit $2.53 Billion by 2029 with Accelerating Growth …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Abemaciclib Market Size Growth Forecast: What to Expect by 2025?
In recent times, there has been a speedy increase in the abemaciclib market size. It is anticipated to rise from $1.42 billion in 2024 to $1.60 billion in 2025, with an annual growth rate of 12.5%. The significant expansion…
Precision Standards for Oncology Research: Exploring Abemaciclib Impurity 1 and …
In the ever-evolving field of targeted cancer therapy, Abemaciclib has emerged as a pivotal agent in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. As researchers and pharmaceutical developers continue to innovate in oncology, the importance of impurity profiling and the availability of reliable Abemaciclib impurity standards has never been greater.
At the forefront of pharmaceutical impurity standards, Aquigen Bio is proud to support global manufacturers, CROs,…
